| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Section of Nuclear Medicine, Department of Experimental Medicine and Pathology, and Departments of Gastroenterology and Internal Medicine, University La Sapienza, Rome, Italy
Correspondence: For correspondence or reprints contact: Orazio Schillaci, MD, P.le G. Douhet 5, 00144 Rome, Italy.
ABSTRACT
Abdominal carcinoid tumors are often small and difficult to localize. Somatostatin receptors have been detected in carcinoids, thus enabling their in vivo visualization by scintigraphy with 111In pentetreotide, a radiolabeled somatostatin analog. The aim of this study was to determine the value of 111In-pentetreotide SPECT in the detection of abdominal carcinoids and to compare these results with the outcomes from planar scans and conventional imaging techniques. Methods: Eighteen patients with a present, or previously operated, abdominal carcinoid were evaluated. Abdominal SPECT scans were acquired 4 hr postinjection of 111In-pentetreotide and multiple planar views were performed at 4, 24, and 48 hr. Results: No adverse reactions were observed after radiopharmaceutical injection. In 13 of 18 patients, abnormal sites of uptake were found by SPECT, which localized 9 abdominal extrahepatic lesions (in 7 patients) and 33 hepatic lesions (in 10 patients).No pathologic accumulation was seen in the five patients considered in complete remission after surgery. Planar scans visualized 5 abdominal extrahepatic sites (in 4 patients) and 21 liver tumor sites (in 7 patients), while conventional procedures detected 3 abdominal extrahepatic lesions (in 2 patients) and 30 hepatic lesions (in 7 patients). Conclusion: Indium-111-pentetreotide scintigraphy is a safe and practical procedure SPECT appears to be more sensitive than planar scintigraphy and conventional methods to detect abdominal carcinoids: it can increase the number of visualized tumor sites and that of patients with positive findings and may therefore have a role not only in the mapping of tumor spread but also in therapeutic decisions.
Key Words: abdominal carcinoid tumors • SPECT • somatostatin recaptor scintigraphy • indium-111-pentetreotide
This article has been cited by other articles:
|
|
 |
|
  O. Schillaci Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: Not Only SPECT? J. Nucl. Med., April 1, 2007; 48(4): 498 - 500. [Full Text] [PDF]
|
|
|
|
 |
|
 J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Gut, June 1, 2005; 54(suppl_4): iv1 - iv16. [Full Text] [PDF]
|
|
|
|
|
|
M. Gabriel, C. Decristoforo, E. Donnemiller, H. Ulmer, C. Watfah Rychlinski, S. J. Mather, and R. Moncayo An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors J. Nucl. Med., May 1, 2003; 44(5): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Schillaci, A. Spanu, F. Scopinaro, A. Falchi, R. Danieli, P. Marongiu, N. Pisu, G. Madeddu, G. Delle Fave, and G. Madeddu Somatostatin Receptor Scintigraphy in Liver Metastasis Detection from Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., March 1, 2003; 44(3): 359 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S E M Clarke Advances in radionuclide imaging: radionuclide imaging as a guide to therapy Imaging, September 1, 2001; 13(3): 171 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hoegerle, C. Altehoefer, N. Ghanem, G. Koehler, C. F. Waller, H. Scheruebl, E. Moser, and E. Nitzsche Whole-Body 18F Dopa PET for Detection of Gastrolintestinal Carcinoid Tumors Radiology, August 1, 2001; 220(2): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
